PHARMA - Life Sciences Tools & Services - AI Impact Report

About This Industry

Makers of laboratory instruments, consumables and bioprocessing equipment, plus contract research organizations (CROs) that run preclinical and clinical studies for drug developers. Customers are pharma and biotech companies, universities and government labs, and diagnostic and industrial labs. AI shows up in three places: inside instruments and lab software, in clinical-trial operations, and as a source of new demand from customers doing AI-driven research.

Representative public companies: Thermo Fisher Scientific (TMO), Danaher (DHR), Agilent Technologies (A), IQVIA Holdings (IQV), Waters (WAT), Illumina (ILMN), Medpace Holdings (MEDP), Charles River Laboratories (CRL). Named for context only, not as recommendations.

Where AI Adoption Stands Now

Research current as of October 1, 2026 · Adoption stage: Bifurcated

By mid-2026, AI in life sciences tools is split between software and data layers that are moving fast and physical lab and trial work that is still done by people. Instrument makers are building AI into their products: Thermo Fisher launched Orbitrap mass spectrometers with AI-driven analytics in the second quarter of 2026 and announced a collaboration with NVIDIA in January to make labs more automated, and Danaher said customers are investing in lab infrastructure for autonomous labs and AI-enabled drug discovery. Among CROs, IQVIA reported 294 AI agents across 90 use cases in July 2026 (vendor-reported), while Medpace's CEO said in April that a net benefit from AI is a few years out. The sharpest market reaction was fear rather than results: CRO shares fell sharply after Anthropic launched AI agents in February 2026, on worries that drugmakers could take trial work in-house, though analysts quoted by Reuters saw no evidence of pharma cutting CRO spending because of AI. End markets improved through mid-2026, with biotech funding recovering, academic demand stabilizing below normal levels, and China mixed.

Verified Deployments

Company	What was deployed	Date
IQVIA Holdings (IQV)	AI agents built with NVIDIA tools and deployed across IQVIA's clinical-trial and commercial work (site start-up and enrollment on clinical studies, commercial analytics) and in client workflows 294 agents across 90 use cases; 19 of the top 20 pharma companies have deployed IQVIA AI solutions and four of the top 10 have contracted to co-develop AI solutions; the CFO said operational and productivity programs, with AI as one lever, drove about 90 basis points of operational margin expansion in the quarter (vendor-reported)	2026-07-28^[1]
Thermo Fisher Scientific (TMO)	Next-generation Orbitrap mass spectrometers with AI-driven analytics launched at the American Society for Mass Spectrometry conference; separate collaboration with NVIDIA (announced January 2026 at the J.P. Morgan Healthcare Conference, per R&D World) to connect instruments, lab software and data to AI tools and increase lab automation Q2 2026 revenue grew 10% to $11.99 billion with 5% organic growth, and full-year revenue guidance was raised to $47.4-$48.1 billion on the Q2 earnings call; the company does not break out AI-attributable revenue	2026-07-23^[2]
Danaher (DHR)	Beckman Life Sciences lab automation sold into autonomous-lab and AI-enabled drug discovery builds; Biacore 8S screening platform with AI-powered data analysis Management said Beckman saw notable growth in automation and described 'little green shoots around the AI dynamic'; bioprocessing orders grew mid-teens in Q2 2026 (company-reported, AI share not quantified)	2026-07-21^[3]
Charles River Laboratories (CRL)	Joined Eli Lilly's TuneLab AI/ML platform as a non-clinical testing partner; introduced an AI-enabled, end-to-end digital pathology workflow Company says the pathology workflow will improve study turnaround times and pathologist efficiency (vendor-reported, no figures); Q2 2026 organic revenue grew 0.1%, with the Research Models and Services segment declining	2026-08-05^[4]
Medpace Holdings (MEDP)	Internal investment in AI for clinical-trial operations CEO said the company will spend more on AI over at least the next two years than it gains in efficiency, and does not see clients' AI use affecting its services yet	2026-04-23^[5]

Future Uses to Watch

Projections grounded in what is happening now, not certainties. Each one names the signal that would confirm it.

AI agents handling routine clinical-trial operations such as site startup, patient pre-screening and recruitment, with people keeping consent, site execution and safety monitoring 12-24 months

IQVIA reported 294 AI agents across 90 use cases in July 2026 and said a client cited its AI-enabled site start-up and enrollment capabilities when awarding a Phase III study (vendor-reported).^[1]

What would confirm it: CROs disclosing shorter enrollment or site-activation times on AI-supported studies, or lower cost per patient

AI analysis built into mass spectrometry and other high-end instruments as a standard feature that drives replacement purchases 12-24 months

Thermo Fisher launched next-generation Orbitrap platforms with AI-driven analytics in the second quarter of 2026 and said it is expanding a suite of AI-powered software for proteomics.^[6]

What would confirm it: Instrument makers citing AI features as a reason for an upgrade cycle, or analytical instrument growth staying above consumables growth

Lab-in-the-loop science: AI agents connected directly to instruments, designing experiments, running them and analyzing results with fewer manual steps 24-36 months

Thermo Fisher and NVIDIA announced a collaboration in January 2026 to progressively increase lab automation, and Danaher said in July that customers are investing in lab infrastructure for autonomous labs.^[7]

What would confirm it: Tools makers reporting automation or AI-enabled instrument revenue as a separate growth line, or a pharma customer publishing throughput gains from an autonomous lab

Gain-share contracts in which CROs and drugmakers split savings from AI-driven trial efficiency 24-36 months

TD Cowen analysts, quoted by Reuters, said they expect new types of contracting to emerge, including gain-share arrangements on AI efficiencies.^[8]

What would confirm it: A large CRO describing outcome- or gain-share pricing on an earnings call, or such terms appearing in a disclosed pharma-CRO agreement

New approach methodologies (in vitro, organ-on-chip and computational models) replacing part of animal testing in preclinical safety work 24-36 months

The FDA issued draft guidance on validating these methods in March 2026, after draft guidance in December 2025 aimed at phasing out primate use for monoclonal antibody testing.^[9]

What would confirm it: Final FDA guidance, and preclinical CROs reporting NAM revenue growing while research-model revenue shrinks

What to Watch Next

FY2027 (federal fiscal year began October 1, 2026): FY2027 Labor-HHS appropriations setting NIH funding: the House committee bill adds $100 million over FY2026, the President's request cuts about 12%^[10]
Q4 2026: Danaher's expected mid-single-digit core revenue growth exit rate, a read on whether bioprocessing orders and AI-linked automation demand turn into revenue^[11]
Not before 2028 (Medpace CEO, April 2026): Whether CROs begin reporting a net cost benefit from AI; Medpace's CEO expects investment to exceed efficiency gains for at least the next two years^[5]

Arguments For

Clinical-trial demand is strong despite the AI scare: IQVIA's R&D Solutions net new bookings were $3.15 billion in Q2 2026, up 19%, a 1.22x book-to-bill, and its CEO said AI in discovery will only increase demand for CRO services.
Analysts doubt drugmakers can bring trials in-house: TD Cowen estimates even a fully AI-enabled trial setup would cut drugmakers' costs only 10%-15%, while it could shorten a late-stage trial from 58 to 47 months.
AI-driven research is starting to show up as orders: Danaher said Beckman Life Sciences saw notable growth in automation tied to autonomous labs and AI-enabled drug discovery, and its bioprocessing orders grew mid-teens in Q2 2026.
Revenue is mostly recurring, which cushions shocks: Danaher reported $20.1 billion of recurring revenue out of $24.6 billion in 2025, about 82%.
End markets improved in 2026: Thermo Fisher raised full-year revenue guidance to $47.4-$48.1 billion, and Agilent's fiscal Q3 2026 core revenue grew 7.3%.

Arguments Against

The AI narrative alone can hit valuations: CRO shares fell sharply after Anthropic launched AI agents in February 2026 on fears that drugmakers could take trial work in-house, even without evidence of spending cuts.
Real AI savings at CROs are slow: Medpace's CEO said it is a few years out before AI yields any net benefit, and IQVIA's 90 basis points of operational margin gains were largely offset, leaving adjusted EBITDA margin up 10 basis points.
Academic and government funding is exposed to US budget fights: the President's FY2027 request would cut NIH about 12% to roughly $41.1 billion, and Danaher said academic demand remained below normal levels.
China is a drag and a policy risk: Illumina reports a rest-of-world growth figure that excludes Greater China because it is on China's Unreliable Entities List, Danaher generated about 11% of 2025 sales in China, and Thermo Fisher said its China academic and government business remains muted.
FDA moves away from animal testing threaten research-model revenue: Charles River's Research Models and Services segment revenue fell 1.8% in Q2 2026 (the company cited lower small research model sales in North America), while the FDA advanced draft guidance on non-animal methods in March 2026.

What's Actually Happening

Picks and shovels for AI biology, with one exposed flank. Instrument makers are building AI into products (Thermo Fisher Orbitrap with AI-driven analytics; Thermo Fisher-NVIDIA lab-in-the-loop collaboration) and Danaher sees customers investing in autonomous-lab infrastructure.

Revenue is mostly recurring (Danaher about 82% in 2025). The exposed flank is the CROs: shares fell sharply after Anthropic launched AI agents in February 2026 on fears pharma would take trial work in-house, though analysts saw no spending cuts and TD Cowen estimates only 10%-15% savings from a fully AI-enabled trial.

IQVIA claims 294 AI agents (vendor-reported); Medpace says net AI benefit is a few years out. Policy risk is front-loaded: the FY2027 NIH request cuts about 12%, Illumina sits on China's Unreliable Entities List, and the FDA's move toward non-animal methods is a risk to Charles River's research-model business.

Who wins:

Existing large players absorb the gains

Our Predictions

A score of 1.00 = no change.
>1.00 means AI (net) boosts this industry's relative value.
<1.00 means AI (net) erodes it.
These are relative scores — how this industry's share of the economy shifts in relation to all 31 industries we track.

Timeframe	Score	Range	In Plain English
1 Year	1.10	1.08 – 1.12	Slight tailwind (+10%)
2 Years	1.24	1.19 – 1.28	AI tailwind (+24%)
3 Years	1.55	1.45 – 1.65	AI tailwind (+55%)
5 Years	2.35	2.15 – 2.55	AI tailwind (+135%)
10 Years	2.95	2.70 – 3.20	AI tailwind (+195%)

Quick Snapshot

Rank among 31 industries
#5 of 31

Overall direction
Lean Bull

Room to grow
High expansion gap

AI adoption gap
60% of value chain still untouched by AI

Boom, Base and Doom Scenarios

The same engine run under three sets of assumptions. The spread between the rows shows the uncertainty. It is not a forecast of which one happens.

Scenario	1 yr	2 yr	3 yr	5 yr	10 yr	Rank
Boom Faster AI progress, energy breakthroughs	1.11	1.25	1.63	2.63	3.38	#6
Base Base case AI progress, current trajectory energy	1.10	1.24	1.55	2.35	2.95	#5
Doom Slower AI progress, constrained energy, market correction	1.05	1.20	1.47	2.09	2.55	#5

Where This Industry Stands with AI

AI Ceiling0.85

How much of this industry CAN AI theoretically affect

Current AI Adoption0.25

How much IS being affected right now

Adoption Speed0.75

How fast AI is actually being deployed

Barriers to Adoption0.60

Regulation, physics, institutional pushback

How We Get These Numbers

Layer 1: Structural Foundation

Built from earnings calls, patent filings, regulatory documents, deployment disclosures and peer-reviewed research. 205 mapped cross-industry relationships. Recalibrated continuously since February 2026, with every parameter change logged.

Layer 2: Live Market Reality

Refreshed with every major development. Real deployment numbers, quarterly earnings data, regulatory shifts (EU AI Act, export controls), and macro conditions like the energy bottleneck. Not a static model — a living one.

Layer 3: Your Scenario (Customizable in our dashboard)

This report uses: Base case AI development pace and Current trajectory energy trajectory. Members can adjust both and see how scores change in real time.

Industries That Affect PHARMA - Life Sciences Tools & Services

When AI changes these industries, it ripples into PHARMA - Life Sciences Tools & Services.

Industry	Effect	Strength	Timing
PHARMA - Big Pharma AI growth in PHARMA - Big Pharma creates demand or opportunities that benefit PHARMA - Life Sciences Tools & Services	Positive	75%	Medium-term
PHARMA - Biotech & AI Drug Discovery AI growth in PHARMA - Biotech & AI Drug Discovery creates demand or opportunities that benefit PHARMA - Life Sciences Tools & Services	Positive	65%	Near-term
SOFTWARE - Cloud & AI Platforms AI growth in SOFTWARE - Cloud & AI Platforms creates demand or opportunities that benefit PHARMA - Life Sciences Tools & Services	Positive	45%	Medium-term
SEMICONDUCTORS - Chip Design & Fabless AI growth in SEMICONDUCTORS - Chip Design & Fabless creates demand or opportunities that benefit PHARMA - Life Sciences Tools & Services	Positive	40%	Medium-term
Health Care Equipment & Services AI changes in Health Care Equipment & Services have complex, mixed effects on PHARMA - Life Sciences Tools & Services	Mixed	40%	Medium-term
Technology Hardware & Equipment AI growth in Technology Hardware & Equipment creates demand or opportunities that benefit PHARMA - Life Sciences Tools & Services	Positive	35%	Medium-term
SEMICONDUCTORS - Foundry & Equipment AI growth in SEMICONDUCTORS - Foundry & Equipment creates demand or opportunities that benefit PHARMA - Life Sciences Tools & Services	Positive	35%	Near-term
SOFTWARE - Enterprise SaaS (AI-Native) AI disruption in SOFTWARE - Enterprise SaaS (AI-Native) may reduce demand or competitiveness for PHARMA - Life Sciences Tools & Services	Negative	35%	Medium-term
...and 2 more